Actively Recruiting
Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab
Led by Sun Yat-sen University · Updated on 2025-09-25
30
Participants Needed
1
Research Sites
75 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Atezolizumab plus bevacizumab is the first-line treatment for advanced hepatocellular carcinoma (HCC). However, the effect of the second-line treatment after the progress of Atezolizumab plus bevacizumab therapy remains unsatisfactory. This is a prospective trial to investigate the efficacy and safety of systemic chemotherapy with FOLFOX plus Atezolizumab \& bevacizumab as second-line treatment for patients with advanced HCC who previously received atezolizumab plus bevacizumab
CONDITIONS
Official Title
Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of hepatocellular carcinoma based on European Association for the Study of the Liver criteria
- At least one tumor lesion measurable by EASL standards
- Barcelona clinic liver cancer stage C
- Prior first-line treatment with atezolizumab plus bevacizumab with tumor progression confirmed by imaging
- No other systemic treatments received
- Eastern Cooperative Oncology Group performance status of 0 to 2
- No cirrhosis or cirrhosis classified as Child-Pugh class A only
- Not eligible for surgical resection, local ablative therapy, or other curative treatments
- Laboratory parameters: Hemoglobin ≥ 8.5 g/dL, Total bilirubin ≤ 30 mmol/L, Serum albumin ≥ 30 g/L, AST and ALT ≤ 5 times upper normal limit, Serum creatinine ≤ 1.5 times upper normal limit, INR ≤ 1.5 or PT/APTT normal, Absolute neutrophil count > 1,500/mm3
- Ability to understand and sign informed consent
You will not qualify if you...
- Evidence of liver decompensation including ascites, gastrointestinal bleeding, or hepatic encephalopathy
- Known history of HIV infection
- History of organ transplant
- Known or suspected allergy to study drugs or related agents
- Cardiac ventricular arrhythmias needing anti-arrhythmic therapy
- Evidence of bleeding disorders
- Clinically significant gastrointestinal bleeding within 30 days prior to enrollment
- Known central nervous system tumors including brain metastases
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510000
Actively Recruiting
Research Team
M
Ming Shi
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here